Synlogic Promotes Aoife Brennan to President & CEO

Aoife Brennan has been appointed president and CEO of synthetic biology company Synlogic (NASDAQ: [[ticker:SYBX]]), effective immediately, the company announced Tuesday. Brennan had been serving as interim president and chief executive of Cambridge, MA, Synlogic since May. She joined the company as chief medical officer in 2016 after six years at Biogen (NASDAQ: [[ticker:BIIB]]). Synlogic is engineering bacteria into “living medicines.” The company’s lead drug programs are in development as treatments for hyperammonemia, or elevated levels of ammonia in the blood.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan